CBL and neoplasm: Using phospho-defective (Y700A) and phosphomimetic (Y700D) mutants, we demonstrate that Tyr700 phosphorylation status dictates CBL's capacity to target PD-L1 for destruction, thereby controlling immunosuppressive PD-L1 abundance in the tumor microenvironment.